In this interview we discuss the latest on HPV vaccines for cancer prevention and some of the struggles countries face in achieving widespread adoption.
Jack Cuzick, PhD
Advertisement
Articles by Jack Cuzick, PhD
The so-called “carryover” effect of tamoxifen results in the reduction in recurrence continuing well after treatment has stopped. The carryover effect is seen mostly in the first 5 years after treatment cessation, and recent evidence suggests that after that time, it is largely over.
Advertisement
Latest Updated Articles
HPV Vaccines Continue to Improve, But More Uptake RequiredSeptember 24th 2015
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
2
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
3
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
4
Achieving a “Functional Cure” With Multiple Myeloma Therapy
5